Check out our new preprint "Convergent Lead Discovery Strategies Yield Covalent and Non-covalent Inhibitors of Human UDP-Galactose-4-Epimerase" on Chemrxiv led by Will Browne in close collab with GSK @jtbush.bsky.social chemrxiv.org/engage/chemr...

🧪 Excited to share our new work on reactive metallo-scaffolds (r-mS)! We combine metal complexes with chemoproteomics to discover new liganding sites across the proteome! Shout out to a great collaboration with GSK! Fantastic team effort 🫶🏻 chemrxiv.org/engage/chemr...

Great paper by the group of @jtbush.bsky.social with first author @harrywilders.bsky.social in @angewandtechemie.bsky.social. They established a direct-to-biology approach to quickly screen covalent protein ligands and advance the covalent hits into a non-covalent inhibitor series. #ChemSky #ChemBio

Interesting paper by the groups of @katrinrittinger.bsky.social and @jtbush.bsky.social in @commschem.bsky.social. DIA-based chemical proteomics in combination with direct-to-biology compound optimization identifies new, enantioselective inhibitors for the DUB OTUD7B. www.nature.com/articles/s42...

Great @chemrxiv.bsky.social preprint by a team of GSK around @jtbush.bsky.social. They showcase the power of single- and multi-step direct-to-biology approaches by developing a potent, cell-active actylamide inhibitor for WRN helicase. chemrxiv.org/engage/...

Excited to share a key part of my postdoctoral work from @crick.ac.uk and GSK, published in Nature Communications. A collaborative project to develop a high-throughput chemoproteomics platform for profiling cysteine-reactive fragments in native biological systems. www.nature.com/articles/s41...

I am happy to share that our recent work has been published in Angewandte Chemie. We demonstrate how ‘direct-to-biology’ screening can accelerate optimisation campaigns, yielding potent covalent and non-covalent inhibitors from reactive fragment hits. onlinelibrary.wiley.com/doi/full/10....